Metabolic engineering combines principles from biochemistry, molecular biology, and systems biology to rewire cellular metabolism for industrial purposes. The discipline was formalized in the early 1990s by Jay Bailey and Gregory Stephanopoulos, who established the framework for rational pathway optimization. Rather than modifying single genes in isolation, metabolic engineers consider the cell as an integrated system, balancing flux through interconnected pathways to maximize production of target molecules while maintaining cell viability.
The modern metabolic engineering workflow leverages computational modeling, high-throughput screening, and machine learning to navigate the vast design space of possible genetic modifications. Companies like Zymergen (acquired by Ginkgo Bioworks) pioneered the application of automation and data science to metabolic engineering, while Amyris demonstrated the commercial viability of engineered microbial production with its artemisinin and squalane platforms. Today, startups like DMC Biotechnologies use dynamic metabolic control to improve production economics, adjusting pathway flux in real time during fermentation.
Key challenges in metabolic engineering include balancing growth versus production, avoiding toxic intermediate accumulation, and achieving economically viable titers, rates, and yields at scale. The integration of cell-free prototyping, biosensor-based screening, and AI-driven pathway design is helping to address these bottlenecks, enabling the bio-based production of chemicals, fuels, and materials that can compete with petrochemical alternatives.